© On 22.06.15, The U.S. Food and Drug Administration approved Cangrelor (Kengreal) which is a new intravenous antiplatelet drug could be used with Percutaneous coronary intervention (PCI) for the treatment of stable angina or acute coronary syndromes (ACS, or myocardial infarction (MI) and unstable angina (UA)).
© Cangrelor (Kengreal) is an intravenous (IV), direct acting, reversible competitive inhibitor of P2Y12 receptor.
Mechanism of Action:
© Cangrelor blocks P2Y12 receptors of Platelet cell membranes causing inhibition of release of ADP and other mediators such as TxA2 and inhibition of activation of Glycoprotein IIb/IIIa which result in to the inhibition of Platelet activation and aggregation.
Adverse Drug Reactions:
© The ADRs such as Dyspnea, Vomiting, Nausea, Headache and Hypotension have been noted with Cangrelor use.
Contraindications:
Cangrelor is contraindicated in patients with significant active bleeding and patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor.
